IWM
NVCR icon

IHT Wealth Management’s NovoCure NVCR Stock Holding History

IHT Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,325
Closed -$337K – 1129
2024
Q4 		$337K Sell
11,325
-213
-2% -$4.51K 0.01% 818
2024
Q3 		$180K Buy
+11,538
New +$209K 0.01% 1098

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

IHT Wealth Management's NVCR Position: Q1 2025 in Review

IHT Wealth Management sold out of NovoCure (NVCR) in Q1 2025, closing a stake of 11,325 shares — an estimated $337K sold.

IHT Wealth Management first reported a position in NVCR in Q3 2024 and held it in 2 quarters. The position peaked at $337K in Q4 2024. 227 funds tracked by Wall St. Rank hold NVCR as of Q1 2025.

  • IHT Wealth Management reported no remaining NovoCure position as of Q1 2025 after selling out during the quarter.
  • IHT Wealth Management sold 11,325 NovoCure shares in Q1 2025, an estimated $337K.
  • IHT Wealth Management first reported a position in NovoCure in Q3 2024 and held it in 2 quarters.
  • IHT Wealth Management's NovoCure position peaked at $337K in Q4 2024.
  • 227 funds tracked by Wall St. Rank held NovoCure as of Q1 2025.

Based on IHT Wealth Management's 13F filing for Q1 2025, filed 15 May 2025.